Acute portal vein thrombosis in noncirrhotic patients – different prognoses based on presence of inflammatory markers: a long-term multicenter retrospective analysis.

Autor: Keil, Radan, Koželuhová, Jana, Dolina, Jiří, Hep, Aleš, Kroupa, Radek, Kojecký, Vladimír, Krejčí, Tomáš, Havlín, Jan, Hadačová, Ivana, Segethová, Jitka, Koptová, Petra, Zádorová, Zdena, Matouš, Jan, Frýbová, Barbora, Chmátal, Petr, Wasserbauer, Martin, Šťovíček, Jan, Bae, Melvin, Guven, Tolga, Zaeem, Mahmood
Předmět:
Zdroj: Scandinavian Journal of Gastroenterology; Nov2019, Vol. 54 Issue 11, p1379-1384, 6p
Abstrakt: Background: Portal vein thrombosis (PVT) is a partial or complete thrombotic occlusion of the portal vein and is rare in noncirrhotic patients. Patients and methods: 78 adult patients with noncirrhotic acute PVT without known malignity were evaluated. Patients with initial CRP level 61–149 mg/l were excluded. Results: Patients were divided into two groups – the first one (33 patients) was characterized with signs of inflammation and CRP over 149 mg/l. The second group (45 patients) was without signs of inflammation and CRP level less than 61 mg/l. The frequency of prothrombotic hematologic factors was statistically significantly different in levels of factor VIII and MTHFR 677 C mutation. All patients from both groups underwent the same oncologic and hemato-oncologic screening which was positive in 23 patients (51.1%) in the group without signs of inflammation. In the group of patients with clinical and laboratory signs of inflammation oncologic and hemato-oncologic screening was positive only in 1 patient (3.0%). Complete portal vein recanalization was achieved in 19.2%, partial recanalization in 26.9%. Conclusions: Patients with clinical signs of inflammation and acute PVT have a low risk of malignancy in contrast to patients without signs of inflammation and acute PVT, which have a high risk of oncologic or hemato-oncologic disease. Patients with negative hemato-oncologic screening should be carefully observed over time because we expect they are at higher risk for the development of hemato-oncologic disease, independent from the presence and number of procoagulation risk factors. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index